Pelotonia Research Center Faculty: Driving Innovation Toward a Cancer‑Free World
At the heart of Ohio State University’s growing commitment to a cancer‑free future is the Pelotonia Research Center Faculty. This distinguished group of scientists, physicians, and educators works within the university’s new innovation district, leveraging cutting‑edge technology and collaborative partnerships to accelerate discoveries from bench to bedside. In 2024, riders, donors, and volunteers will once again join forces to pedal toward a cancer‑free world through the annual Pelotonia ride, underscoring the vital link between community support and research progress.
Origins and Institutional Support
The word “Pelotonia” stems from the Greek “peloton,” meaning a group moving together toward a common goal. This spirit of collective effort was recognized when the Ohio State University Board of Trustees voted to formally acknowledge the Pelotonia initiative as a cornerstone of the university’s cancer research strategy. The Ohio State University Wexner Medical Center, a leading academic health system, provides the clinical backbone that enables faculty to translate laboratory findings into patient‑centered therapies.
Faculty Composition and Expertise
Interdisciplinary Talent Pool
The Pelotonia Research Center Faculty comprises more than 150 members spanning multiple disciplines:
- Basic scientists specializing in molecular biology, genomics, and immunology.
- Clinical researchers who design and conduct trials in oncology, hematology, and precision medicine.
- Engineering innovators developing novel drug‑delivery platforms and imaging technologies.
- Data scientists applying artificial intelligence to predict treatment responses.
Each faculty member is selected for a proven track record of high‑impact publications, successful grant acquisition, and a commitment to mentorship.
Leadership and Notable Scholars
Key leaders include:
- Dr. Emily Rivera, Director of Translational Oncology, whose work on tumor‑microenvironment signaling has led to two FDA‑approved therapies.
- Prof. Michael Chen, Chair of Computational Biology, recognized for pioneering machine‑learning models that stratify patients for personalized treatment.
- Dr. Aisha Patel, Senior Investigator in Immunotherapy, whose CAR‑T cell research earned a National Cancer Institute Innovation Award.
